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Abstract 
Background: Withdrawal syndrome may influence patient's motivation for participation in addiction 
treatment programs. Management of the symptoms can improve the success rate of addiction treatment 
programs. In the present study, we have evaluated the efficiency of an herbal product as adjunct therapy for 
alleviation of withdrawal syndrome in opium abuse. 
Methods: In the present clinical trial, 81 patients were assigned into case and control groups. The control 
group was treated with methadone and placebo for 4 weeks. The case group was treated with methadone and 
powdered dried leaves of Rosmarinus officinalis for the same interval. Occurrence of withdrawal syndrome 
was compared between groups on days 3, 7, and 14 after beginning of the treatment, and the possible signs 
and symptoms of withdrawal syndrome were checked. The clinical opioid withdrawal scale (COWS) was used 
for evaluation of withdrawal syndrome in the patients. 
Findings: Patients in the case group experienced less severe withdrawal syndrome compared to those in the 
control group; chiefly bone pain, perspiration, and insomnia. 
Conclusion: The present study showed that rosemary can be used as an optional extra drug for treatment of 
withdrawal syndrome during treatment programs for opium addiction and possibly addiction to other 
opioids. 
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Introduction 
The global epidemic of opiate use continues to 
spread, especially in developing countries. 
Research centers have focused on nonaddicting 
opioids or agents that have the capability to 
prevent the addiction process; however, the 
problem has not yet been solved.1 Opioid 
withdrawal symptoms consist of dysphoric mood, 
nausea or vomiting, muscle aches, lacrimation, 
rhinorrhea, pupil dilation, piloerection, sweating, 
diarrhea, yawning, fever, and insomnia.2 
Medications that are used to reduce symptoms of 
opioid withdrawal syndrome have different 
mechanisms. However, their prescription has its 
own limitations and side effects.2 Earlier studies 
conducted on animals have suggested that 
Rosmarinus officinalis (rosemary) can be effective 
in alleviation of symptoms of opioid withdrawal 
syndrome.3,4 
Rosemary grows in many parts of the world.5 It 
is used fresh, dried, or as essential oil.6 Chemical 
content of the plant consists of flavonoids, phenols, 
volatile oils, and terpenoids.7 Rosmarinus officinalis 
acts as antispasmodic, smooth muscles relaxant, 
memory booster, antioxidant, inducer of neural 
growth factor, and anti-microbial agent.5,8-11 It has 
also been claimed that the plant is effective in 
treatment of headache, musculoskeletal pains, and 
seizures.12-14 Analgesic effects of aqueous and 
alcoholic extract of Rosmarinus officinalis have been 
antagonized by naloxone. This may imply its 
interaction with opioid receptors.3,4 
Use of Rosmarinus officinalis has been 
approved as supplemental therapy for 
dyspepsia.15 It has been approved for oral use as 
food supplement in humans by the FDA.16 The 
effects of Rosmarinus officinalis on improvement 
of withdrawal symptoms in morphine 
dependence have been studied in mice.3 It has 
been suggested that it may reduce symptoms of 
withdrawal syndrome by inducing GABA 
system.3 In the present study, we have evaluated 
the use of rosemary as an herbal drug for 
treatment of opium withdrawal syndrome. 
Methods 
The present study which was a randomized clinical 
trial has been performed in Arak city, Iran. It is 
registered in IRCT (register number: 
IRCT138903054033N1). Its details are cited in the 
website of International Clinical Trials Registry 
Platform of WHO 
(http://apps.who.int/trialsearch). It has been 
approved by the local Ethical Committee of Arak 
University of Medical Sciences, Arak, Iran. 
The patients participated in the study if they had 
the inclusion criteria. They were selected from drug 
abusers referred to a rehabilitation clinic of a 
teaching university hospital. The inclusion criteria 
were: any form of abuse of opium at least 2.3 grams 
per day continuously for at least one year, age 
between 20-50 years, no history of any major 
medical disease, and no history of sensitivity to the 
plant. Eighty was determined as the target sample 
size, as approved by a biostatician. 
Half of the patients were randomly assigned as 
control group. The other half was allocated as case 
group. The exclusion criteria were failure to 
follow up, allergy to rosemary, and continued use 
of opium during the trial. 
Both groups were treated by methadone for 
short-term detoxification. They received 20 
mg/day in the 1st week, then 15 mg/day in the 2nd 
week, followed by 10 mg/day in the 3rd week, and 
5 mg/day in the 4th week. The rosemary capsules 
(filled with dried powdered leaves) had been 
produced by Barij Essence Pharmaceutical 
Company, Kashan, Iran, and contained 300 mg 
dried leaves of Rosemary. They were 
administrated to the patients in the case group as 
16 capsules/day for the first 3 days, 12 
capsules/day for the following 4 days, and then 8 
capsules for the next week in divided doses. 
Patients in the control group received placebo 
produced by the same company. All patients were 
visited in the 3rd, 7th, and 14th day after starting of 
the treatment by a physician. The physician and 
the patients in the case and control groups did not 
know anything about the content of the capsules 
and which patient belongs to which group. 
The clinical opioid withdrawal scale (COWS) 
was used for evaluation of withdrawal syndrome 
in the patients. In addition, sleep duration and 
insomnia were evaluated in the patients.  
The results were compared between the 2 
groups using paired t-test. SPSS for Windows 
(version 11.5; SPSS Inc., Chicago, IL., USA) was 
used for statistical analysis. 
Results 
98 patients participated in the study. 17 patients  
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Table 1. General characteristics of the studied patients 
 Case group (n = 39) Control group (n = 42) P 
Age 36.7 ± 4.58 36.6 ± 7.53 Not significant 
Male/female ratio All were male All but one were male Not significant 
Mean opium use (gram/day, as 
stated by the patients) 1.8 ± 0.43 1.7 ± 0.51 Not significant 
Mean duration of opium abuse 
(years, as stated by the patients) 10.1 ± 5.21 10.2 ± 6.08 Not significant 
 
failed to finish their treatment course, mainly due 
to failure to follow up (9 patients) and continued 
use of opium (6 patients). General characteristics 
of the patients have been demonstrated in table 1. 
Mean COWS score was 9.2, 7.5, and 6 in the 
case group in the 3rd, 7th, and 14th days of 
treatment, respectively. The corresponding scores 
were, respectively, 12.1, 11.7, and 7.8 in the 
control group. The differences were statistically 
significant for the 3rd and 7th days (P < 0.050). 
There were significant differences between 
duration of sleep in 3rd and 7th days between case 
and control groups (P < 0.001 and P < 0.002, 
respectively). More details have been displayed in 
table 2. 
 
Table 2. Mean duration of sleep per day in case and 
control groups 
Group 3
rd day 
(hours) 
7th day 
(hours) 
14th day 
(hours) 
Case 6.5 6.9 7.3 
Control 5.0 5.5 6.1 
 
Furthermore, as can be seen in table 3, there 
was significant difference in the percentage of 
patients who were complaining from insomnia 
between case and control groups on 3rd and 7th 
days (P < 0.001). 
 
Table 3. Percentage of patients with insomnia in case 
and control groups after the treatment 
Group 3rd day (%) 7th day (%) 14th day (%) 
Case 25.0 12.5 15.0 
Control 77.5 72.5 20.0 
 
Discussion 
Results of the present study confirmed that 
rosemary can be used as an adjunct therapy for 
improvement of withdrawal syndrome during 
addiction treatment programs. Hosseinzadeh et al. 
have stated that muscle jerks are the main criteria 
of morphine withdrawal syndrome. In their study 
performed on rats, it has been suggested that 
rosemary can reduce muscle jerks produced by 
morphine withdrawal syndrome.4 In another 
study, the effectiveness of aqueous and alcoholic 
extract of rosemary in reduction of opium 
withdrawal syndrome in animals has been 
proved.3 In the study of Boroushaki et al., the 
therapeutic effect of rosemary in treating 
convulsion was evaluated in comparison with 
phenobarbital. It was verified that all parts of the 
plant can reduce convulsion in animals.14 In our 
study, the effectiveness of rosemary in the 
improvement of sleep and reduction of insomnia 
was demonstrated. It is likely that the 
anticonvulsant effect, found in the former study, 
occurs with the same mechanism as rosemary's 
affect on reducing insomnia in the present study. 
Moreover, it was shown that rosemary can reduce 
musculoskeletal pain.13 In the current study, the 
effectiveness of rosemary in reduction of 
musculoskeletal pain in opium addicts has also 
been demonstrated. 
In summary, results of the current study reveal 
that Rosmarinus officinalis can improve opioid 
withdrawal syndrome to some extent. This can be 
attributed to various properties of the plant, 
including anti-inflammatory and 
psycho-stimulant effects.17,18 Extraction of 
alkaloids present in the plant may elucidate true 
constituents of the alkaloid(s) responsible for this 
effect.  
Conclusion 
The present study showed that rosemary can be 
used as an herbal drug for treatment of withdrawal 
syndrome during treatment programs for opium 
addiction and possibly addiction to other opioids. 
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ﺗﺮﻳﺎك در  ﺗﺄﺛﻴﺮ ﻣﻔﻴﺪ ﮔﻴﺎه رزﻣﺎرﻳﻨﻮس اﻓﻴﺸﻴﻨﺎﻟﻴﺲ در درﻣﺎن ﺳﻨﺪرم ﻣﺤﺮوﻣﻴﺖ ﻧﺎﺷﻲ از
  ﻫﺎي ﺗﺮك اﻋﺘﻴﺎد ﺑﺮﻧﺎﻣﻪ
  
  ،5زاده ، دﻛﺘﺮ ﻣﺤﺴﻦ ﺗﻘﻲ4، دﻛﺘﺮ ﺷﻴﺮﻳﻦ ﭘﺎزوﻛﻲ3، دﻛﺘﺮ ﻋﺒﺎس ﻋﻠﻴﻤﺮادﻳﺎن2، دﻛﺘﺮ ﺑﻬﻤﻦ ﺻﺎﻟﺤﻲ1ﺣﺴﻦ ﺻﻠﺤﻲدﻛﺘﺮ 
  6ﻓﺮ دﻛﺘﺮ اﻣﻴﺮ ﻣﺤﻤﺪ ﻛﺎﻇﻤﻲ، 5دﻛﺘﺮ ﻋﻠﻲ ﻣﺤﻤﺪ ﺻﺎﻟﺢ
  
  
  ﭼﻜﻴﺪه
ﻛﻨﺘﺮل ﻋﻼﻳﻢ ﺳﻨﺪرم . ﻫﺎ اﺧﺘﻼل اﻳﺠﺎد ﻛﻨﺪ آنﻫﺎي درﻣﺎﻧﻲ ﺗﺮك اﻋﺘﻴﺎد و ﺗﻤﺎﻳﻞ ﺑﻴﻤﺎر ﺑﺮاي ﻣﺸﺎرﻛﺖ در  ﺗﻮاﻧﺪ در ﺑﺮﻧﺎﻣﻪ ﺳﻨﺪرم ﻣﺤﺮوﻣﻴﺖ ﻣﻲ :ﻣﻘﺪﻣﻪ
در اﻳﻦ ﻣﻄﺎﻟﻌﻪ اﺛﺮ ﻳﻚ داروي ﮔﻴﺎﻫﻲ ﺑﻪ ﻋﻨﻮان داروي ﻣﻜﻤﻞ در ﺑﻬﺒﻮد ﻋﻼﻳﻢ . ﺗﻮاﻧﺪ ﺷﺎﻧﺲ ﻣﻮﻓﻘﻴﺖ در ﺗﺮك اﻋﺘﻴﺎد را ﺑﻬﺒﻮد ﺑﺨﺸﺪ ﻣﺤﺮوﻣﻴﺖ ﻣﻲ
  .ﺳﻨﺪرم ﻣﺤﺮوﻣﻴﺖ ﻧﺎﺷﻲ از اﻋﺘﻴﺎد ﺑﻪ ﺗﺮﻳﺎك، ﻣﻮرد ارزﻳﺎﺑﻲ ﻗﺮار ﮔﺮﻓﺖ
ﻫﻔﺘﻪ ﺗﺤﺖ درﻣﺎن ﺑﺎ  4ﮔﺮوه ﺷﺎﻫﺪ ﺑﺮاي ﻣﺪت . ﺑﻴﻤﺎر در دو ﮔﺮوه ﻣﻮرد و ﺷﺎﻫﺪ ﺗﺤﺖ ﻣﻄﺎﻟﻌﻪ ﻗﺮار ﮔﺮﻓﺘﻨﺪ 18در ﻛﺎرآزﻣﺎﻳﻲ ﺑﺎﻟﻴﻨﻲ ﺣﺎﺿﺮ،  :ﻫﺎ روش
ﻫﺎي ﺧﺸﻚ ﺷﺪه و ﭘﻮدر ﺷﺪه ﮔﻴﺎه رزﻣﺎرﻳﻨﻮس  ﻫﺎي ﺣﺎوي ﺑﺮگ ﮔﺮوه ﻣﻮرد ﺑﺮاي ﻫﻤﻴﻦ ﻣﺪت ﺗﺤﺖ درﻣﺎن ﺑﺎ ﻣﺘﺎدون و ﻛﭙﺴﻮل. ﻣﺘﺎدون و داروﻧﻤﺎ ﺑﻮدﻧﺪ
ﺑﺮاي ارزﻳﺎﺑﻲ ﻋﻼﻳﻢ ﺳﻨﺪرم ﻣﺤﺮوﻣﻴﺖ . روز ﭘﺲ از درﻣﺎن از ﻧﻈﺮ ﻋﻼﻳﻢ ﺳﻨﺪرم ﻣﺤﺮوﻣﻴﺖ ارزﻳﺎﺑﻲ ﺷﺪﻧﺪ 41و  7، 3ﺑﻴﻤﺎران . ﻴﺲ ﻗﺮار ﮔﺮﻓﺘﻨﺪاﻓﻴﺸﻴﻨﺎﻟ
  .اﺳﺘﻔﺎده ﮔﺮدﻳﺪ( elacs lawardhtiw dioipo lacinilC) SWOCدر ﺑﻴﻤﺎران از ﻣﻌﻴﺎر 
ﺧﻮاﺑﻲ و  اﻳﻦ ﺗﻔﺎوت ﺑﻪ وﻳﮋه در ﻣﻮرد ﺗﻌﺮﻳﻖ، ﺑﻲ. ﺎﺑﻞ ﺗﻮﺟﻬﻲ ﻛﻤﺘﺮ از ﮔﺮوه ﺷﺎﻫﺪ ﺑﻮدﺷﺪت ﻋﻼﻳﻢ ﺳﻨﺪرم ﻣﺤﺮوﻣﻴﺖ در ﮔﺮوه ﻣﻮرد ﺑﻪ ﻣﻴﺰان ﻗ :ﻫﺎ ﻳﺎﻓﺘﻪ
  .درد اﺳﺘﺨﻮاﻧﻲ ﭼﺸﻤﮕﻴﺮﺗﺮ ﺑﻮد
ﻫﺎي درﻣﺎﻧﻲ  ﺗﻮان از ﮔﻴﺎه رزﻣﺎري ﺑﻪ ﻋﻨﻮان داروي ﻣﻜﻤﻞ ﺟﻬﺖ ﻛﻨﺘﺮل ﻋﻼﻳﻢ ﺳﻨﺪرم ﻣﺤﺮوﻣﻴﺖ در ﺑﺮﻧﺎﻣﻪ ﻣﻄﺎﻟﻌﻪ ﺣﺎﺿﺮ ﻧﺸﺎن داد ﻛﻪ ﻣﻲ :ﮔﻴﺮي ﻧﺘﻴﺠﻪ
  .ﺳﺎﻳﺮ اﭘﻴﻮﺋﻴﺪﻫﺎ ﺑﻬﺮه ﺟﺴﺖﺑﺮاي ﺗﺮك ﺗﺮﻳﺎك و ﺷﺎﻳﺪ 
  ﺳﻨﺪرم ﻣﺤﺮوﻣﻴﺖ، رزﻣﺎرﻳﻨﻮس اﻓﻴﺸﻴﻨﺎﻟﻴﺲ، ﺗﺮﻳﺎك، اﻋﺘﻴﺎد :واژﮔﺎن ﻛﻠﻴﺪي
ﺗﺄﺛﻴﺮ ﻣﻔﻴﺪ ﮔﻴﺎه  .اﻣﻴﺮ ﻣﺤﻤﺪ ﻓﺮ ، ﻛﺎﻇﻤﻲﻋﻠﻲ ﻣﺤﻤﺪ ﺻﺎﻟﺢ ،ﻣﺤﺴﻦ زاده ، ﺗﻘﻲﺷﻴﺮﻳﻦ ، ﭘﺎزوﻛﻲﻋﺒﺎس ، ﻋﻠﻴﻤﺮادﻳﺎنﺑﻬﻤﻦ ﺣﺴﻦ، ﺻﺎﻟﺤﻲ ﺻﻠﺤﻲ :ارﺟﺎع
  :(3-4) 5؛ 2931 ﻣﺠﻠﻪ اﻋﺘﻴﺎد و ﺳﻼﻣﺖ .ﻫﺎي ﺗﺮك اﻋﺘﻴﺎد ﻣﺤﺮوﻣﻴﺖ ﻧﺎﺷﻲ از ﺗﺮﻳﺎك در ﺑﺮﻧﺎﻣﻪرزﻣﺎرﻳﻨﻮس اﻓﻴﺸﻴﻨﺎﻟﻴﺲ در درﻣﺎن ﺳﻨﺪرم 
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  19/01/12: ﺗﺎرﻳﺦ ﭘﺬﻳﺮش  19/7/61: ﺗﺎرﻳﺦ درﻳﺎﻓﺖ
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